MAPT and Alzheimer disease: From a set of upcoming biomarkers (Fagan and Perrin, 2012), the most-established biomarkers for AD diagnosis in cerebrospinal fluid (CSF) are still the determination of Aβ42, total-Tau and phospho-Tau181 (Di Carlo et al., 2012).